Navigation Links
Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
Date:10/10/2008

SEATTLE, Oct. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company intends to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which requires a minimum market value of listed securities of $50 million. CTI received a Staff Determination Letter from The NASDAQ Stock Market LLC on October 7, 2008 indicating that the Company had not regained compliance with this rule during the time period provided by NASDAQ in a previous notice as disclosed in the Company's press release dated September 6, 2008, and therefore does not currently meet the continued listing requirements for The NASDAQ Global Market. Accordingly, the Company's common stock would be subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel. Following the hearing request, the Company's common stock will continue to be listed on The NASDAQ Stock Market pending the conclusion of the hearing process and during any extension period which may be granted by the Panel. It is expected that the hearing would be held within 45 days and that the Panel has discretion to grant an extension not to exceed 180 days from the date of the Staff notification. The Company believes that the notice and any decision by the Panel will have no effect on the ability to trade the securities on the Borsa Italiana.

Alternatively, the Company may apply to transfer its securities to The NASDAQ Capital Market which maintains a lower threshold of financial, qualitative and liquidity requirements if it satisfies the continued inclusion requirements for that market, which include a minimum aggregate market value of listed securities of $35 million. The NASDAQ Capital Market is a continuous trading market that operates in the same manner as The NASDAQ Global Market.

As of October 9, 200
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
4. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
5. Alba Therapeutics Corporation Announces Promotions
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
8. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
9. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
10. Halozyme Therapeutics to Host Research Day for Investors and Analysts
11. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... 4 Researchers are taking a closer...) pathway as studies continue to demonstrate that ...growth, reports Genetic Engineering & Biotech...iogenesis, cell growth, differentiation, and survi...athway, which plays a key role in cancer, accordin...
(Date:12/4/2008)...ec. 4 Imaging Diagnostic...neer in laser optical breast,imaging, announced t...s an,adjunct to mammography is featured in the De... (Logo: http://www.newscom.com/cgi-bin/prnh/2004...radiologist at Charite Hospital in Berlin,German...
(Date:12/4/2008)...4 Raymond J. De Hont, Ch...oration (NYSE: MPR ), announced today that the Co...cember 3, 2008, declared a quarterly dividend of $...olders of record at the close of business on Febru...rease over the same period last year. , , T...
(Date:12/4/2008)...wswire/ -- Azur Pharma Limited ("Azur") today,ann...ment with BioSante,Pharmaceuticals, Inc ("BioSant...estrin(TM). Elestrin is a fast drying gel formulat...ment of moderate to severe vasomotor symptoms,ass...he U.S. Food and Drug,Administration ("FDA") in D...
Breaking Biology Technology:GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research 2Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2Met-Pro Corporation Declares Quarterly Dividend 2Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2
... Promega Corporation ,Source: www.promega.com F...gy companies will receive $250,000 each in tax cre... Jim Doyle announced on Tuesday. , ,Placon Corpora...r, will use the tax relief to create 19 new jobs, ...te 26, officials said. , ,Both companies are in th...
... The recent growth in popularity of two personal...cellular phones with cameras installed, has left e...liability for employers. , ,In 2002, vendors shipp...they shipped 50 million. Instant messaging has bec...gement Association and the ePolicy Institute relea...
... MILWAUKEE Before a technology entrepreneur can...ly growing business, he needs to identify one or m...gel investments. , ,This is not an easy thing to d...h community, Peter M. Skanavis is doing everything...to make angel investments to actually take the plu...
... CHICAGO In last weeks column, I raised the pre...bout making money but about providing radically ne...awn to the early years of rock n roll where it was...what was going on in society (without getting jail...oney and both have become industries that have bec...
Other Biology Technology:Is your employee handbook evolving with technology? 2Is your employee handbook evolving with technology? 3Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 2Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 3Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 4Biotech IPOs bring in encouraging sums 2Biotech IPOs bring in encouraging sums 3
(Date:12/3/2008)...big and heavy, with seemingly little prayer of esc...like a grounded teenager who knows where the car k... chance of escape. , University of Florida resea... landscape devoted to wildlife corridors greenway...covered the pea and similar species share, given a...
(Date:12/3/2008)... suggests that evolution can behave as differently...rgy-efficient style of four-footed running over lo...e evolved a profoundly inefficient gait, tailor-ma..., "It is usually assumed that efficiency is what...e associate professor of evolutionary anthropology...
(Date:12/3/2008)...that individuals can respond just as well to place...ther hand, it is difficult to explain why only cer...esearchers from Uppsala University and Gothenburg ...mpact the placebo effect and a mechanism in the br...os. , The study, published in Journal of Neuros...
(Date:12/3/2008)... first tandem mission between ERS-2 and Envisat la...r again to help improve our understanding of the p...visat, the largest environmental satellite ever bu...truments that provide high resolution images of th...R images of the same site, slight alterations that...
Breaking Biology News(10 mins):Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Dogs chase efficiently, but cats skulk counterintuitively 2Genes determine whether sugar pills work 2ESA satellites flying in formation 2Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 1Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 2Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 3Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 4Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 5New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 1New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 2New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 3New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 4The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 1The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 2The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 3The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 4The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 5JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 1JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 2JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 3
...c analysis of soil samples indicates that a group ...th,s most abundant land-based creatures that oxidi...researchers from Norway, Germany, United Kingdom a...ocess known as nitrification, combine ammonia with...nts by plants. , "Ammonia oxidation is an impo...
...trician well known for his care of and research in...ry changes can affect a woman,s chances of having ...y a combination of diet and heredity. By comparing...animal products, with that of women who do eat ani... physician at Long Island Jewish (LIJ) Medical Cen...
...udy, published today in the current issue of the P... significant implications for the design of diseas...ed in human biomedical research. The groundbreakin...-Substrate Interactions with Luminescent Quantum D...eplace conventional organic dyes in biomedical app...
...st research on water - still one of the least unde...ve study ?seems to support the possibility that ce...be cyropreserved without formation of damaging ice...earcher Anatoli Bogdan, Ph.D. , He conducted the s...ournal of Physical Chemistry B , one of 34 peer-re...
Other Biology News:Ammonia-loving archaea win landslide majority 2Ammonia-loving archaea win landslide majority 3Study finds that a woman's chances of having twins can be modified by diet 2Study finds that a woman's chances of having twins can be modified by diet 3Connect the Quantum Dots 2Slow-frozen people? Latest research supports possibility of cyropreservation 2
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli.
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications).
Biology Products: